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The success of hematopoietic stem cell transplantation (HSCT) lies with the ability of 
the engrafting immune system to remove residual leukemia cells via a graft-versus- 
leukemia effect (GvL), caused either spontaneously post-HSCT or via donor lymphocyte 
infusion. GvL effects can also be initiated by allogenic mismatched natural killer cells, 
antigen-specific T cells, and activated dendritic cells of leukemic origin. The history and 
further application of this GvL effect and the main mechanisms will be discussed and 
reviewed in this chapter.
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iNTRODUCTiON
Allogeneic hematopoietic stem cell transplantation (HSCT) transplantation has a major role in the 
treatment of leukemia and hematological disease, often the only treatment providing a chance of 
cure in otherwise refractory diseases. The primary approaches involved total body irradiation (TBI) 
(1) or cyclophosphamide (CY) (2). However, TBI alone was not immunosuppressive enough, and 
only one patient survived as a chimera (3). CY was readily immunosuppressive, but did not affect 
leukemic stem cells (2). Recovery from aplastic anemia was even observed after CY and graft failure, 
indicating the weak effect of CY on hematopoietic stem cells (4). Sustained success was reported 
with the combination of TBI and CY and other chemotherapy (5), as well as with the combination 
of CY and busulfan (6). In the 1970s and 1980s, interest focused on the conditioning treatment and 
the prevention of graft-versus-host disease (GvHD).
The first suggestion of a graft-versus-leukemia (GvL) effect was in 1956, using a mouse transplanta-
tion model, where rejected leukemia cells appeared to be eliminated by incoming bone marrow when 
irradiation was delayed (7). This led to the concept that the donor marrow cells may be responsible 
for the eradication of the leukemia.
This observation was applied to the clinic nearly 10 years later by Mathé and team in 1965. Mathé 
coined the term “adoptive immunotherapy” for the treatment of leukemia with allogeneic bone 
marrow transplantation (8) and showed that leukemia was eliminated by the GvL. In this paper, 
they also describe the “secondary syndrome,” later to be described as GvHD. Interestingly, bone 
marrow from six family donors were used for the transplant and in order to decide which donor 
may be used posttransplant to enhance GvL, the patient received skin grafts from all six donors. 
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Histocompatibility tests at that time (9, 10) showed that the only 
skin graft, which was not rejected was the one which was closest 
genetically to the donor. This donor was subsequently used to 
give incremental doses of leukocyte treatment posttransplant and 
gave rise to GvL, but also GvHD. The latter was controlled by 
the use of hydrocortisone. The patient remained in remission for 
1-year posttransplant but died from a viral infection with no sign 
of relapsing disease.
A major step toward successful transplantation was identify-
ing HLA-identical siblings as best donors and syngeneic twins for 
prevention of rejection and GvHD. These findings were derived 
from dog experiments where the correct littermate was chosen 
by first ensuring that the donor leukocytes were negative, both 
against the donor in mixed lymphocyte reactions and with cyto-
toxic antisera (11, 12).
In 1990, over 2,000 transplants had been performed and 
reported by the International Bone Marrow Transplant Registry 
(IBMTR). An analysis of the transplants by Horowitz et al. showed 
conclusively that a GvL effect was important to reduce relapse. 
An increased relapse rate was observed when the graft was T cell 
depleted to prevent GvHD. In addition, the data showed that 
grafts with or without T  cells had a high incidence of relapse, 
indicating that the antileukemia effect could occur independent 
of GvHD (13).
Relapse of residual disease is a common cause of reduced 
survival following HSCT. This occurs in 20–70% of patients and 
is dependent on several factors including pretransplant disease 
status, cytogenetic subtypes [in acute myeloid leukemia (AML) 
and in acute lymphoid leukemia (ALL)], stem cell source, age of 
the patient and donor, and type of conditioning regimen (14, 15). 
In addition, relapse contributes to 40–45% of deaths following 
HLA-matched identical HSCT and 34% in unrelated donor 
HSCT (16). The use of reduced intensity conditioning regimens 
has also led to GvL effects, which have been most marked in 
chronic myeloid leukemia (CML) and are also detectable in mye-
lodysplastic syndrome (MDS), AML, and ALL.
This review describes the history and advances made in 
treating and or preventing relapse following HSCT using donor 
lymphocyte infusion (DLI), allogenic mismatched natural killer 
(NK) cells, antigen-specific T cells, and activated dendritic cells 
(DCs) of leukemic origin.
CLiNiCAL ReSULTS USiNG DLi FOR 
ReLAPSe AFTeR HeMATOPOieTiC CeLL 
TRANSPLANTATiON
Although adoptive transfer of lymphocytes immediately after 
transplantation was attempted to induce remission, severe GvHD 
ensued and was unsuccessful for reducing relapse in high risk 
acute leukemia (17).
Careful studies in dogs given T  cell-depleted marrow from 
dog lymphocyte antigen-identical littermate donors had shown 
that donor lymphocytes could be transfused after more than 
2  months posttransplant without the risk of GvHD (18); this 
effect was subsequently shown in both canine and murine trans-
plant models (18–21). Moreover, donor DLI converted mixed 
chimerism into complete chimerism, transferred immunity, and 
improved immune reactivity to leukemic antigens. Further work 
demonstrated the potential role of tolerance in the lack of GvHD 
development.
It took pioneering work in the 1990s (22, 23) to show that, for 
CML transplant patients, subsequent separation of the transplant 
by 2  months from the DLI enabled remissions and prevented 
GvHD. These first studies in man for CML were carried out 
by Kolb and colleagues with subsequent remission in all three 
patients for over a decade (22). Two of the three patients, treated 
in this first report of DLI, are still in complete remission (CR1) 
of CML (22). One patient had a cytogenetic relapse 20 years after 
DLI. She was retreated with DLI from her brother and responded 
again. The GvL effect has been confirmed for CML in numerous 
studies worldwide (24, 25) and are frequently durable offering 
potential cure for the majority of CML patients (26–28). These 
results have been collected by the European group for Blood and 
Marrow Transplantation (EBMT) (29), the US (26), and Japanese 
transplant centers (30). The best results with 70–80% cytogenetic 
complete remissions were reported for CML in cytogenetic and 
hematological relapse, other important factors being the presence 
of chronic GvHD prior to DLI and the time of relapse post-HSCT 
(31). Donor chimerism was also necessary for a successful GvL 
in CML. For patients with AML or MDS, the response rate to 
DLI is much lower (20–40%) and is lower still in ALL (10–13%) 
with intermediate results (40–52%), compared with CML, being 
obtained in multiple myeloma (MM) (32). In AML, DLI efficacy 
is thought to be limited to a small sub group of patients, those 
with favorable cytogenetics, with a low-tumor burden at relapse 
or in hematological remission prior to DLI (33). In general, com-
plete remissions were durable in CML and only in a minority of 
patients with acute leukemia and MM (34).
THe HiSTORY OF THe ROLe OF T CeLLS 
AND NK CeLLS iN THe GvL eFFeCT
As stated previously, the role of T cells was further identified by 
studies using data from the IBMTR (35). In addition, differences 
in relapse rates with higher doses of TBI and fractionated TBI 
versus single-dose TBI were only seen in patients given T-cell-
depleted marrow, while in patients given T-replete marrow, no 
differences were observed (35). In 2004, Ballester et al. described a 
graft versus myeloma effect after DLI and an autologous stem cell 
transplant rescue (36). Daguindau et al. described an antitumor 
effect of HSCT in 14 patients with either acute leukemia or MDS 
who sustained a long-lasting CR1, despite only transient or absent 
engraftment with donor cells (37). This effect, therefore, being 
caused by transient exposure to allogenic T cells and autologous 
reconstitution.
Natural killer cells were identified in the 1970s by Kiessling 
and Wigzell (38) and were shown to kill tumor cell lines in 
the absence of MHC class I molecules (39). This gave rise to 
Ljunggren and Karre in 1990 introducing the “missing self ” 
hypothesis (40) where NK  cells kill targets because they do 
not express high levels of “self ” MHC class I gene products. 
They predicted the presence of receptors for self-MHC which, 
FiGURe 1 | Donor-versus-recipient natural killer (NK) alloreactivity. 
NK cell function is regulated by KIR interactions with matched HLA class I 
alleles. If HLA is mismatched in transplant recipient leukemic cells, NK cells 
are relieved from inhibition and induce cell lysis. In the case for inhibitor KIRs, 
binding with matching HLA prevents donor NK cell activation to self. For 
activating KIRs, donor NK cells that bind the matched HLA are activated and 
induce cell lysis of transplant recipient acute myeloid leukemia (AML) cells. 
Image adapted from Ref. (48, 49).
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when engaged, would inhibit cytotoxicity. It was subsequently 
shown that NK  cells can distinguish between normal and 
malignantly transformed cells by the presence of killer-cell 
immunoglobulin-like receptors (KIRs); these are receptors 
for MHC class I and are the main inhibitory receptors. The 
KIR inhibitory receptor family recognizes HLA-A, B, and C 
molecules (41, 42). Another inhibitory receptor C type lectin 
NKG2A recognizes the MHC molecule HLA-E (43–45). The 
inhibitory receptors give rise to a repertoire of NK  cells with 
overlapping specificities. The function of NK cells is regulated 
by the balance of activatory and inhibitory signals transmitted 
by different cell surface receptors, such as KIRs, NK Group 2 
member D (NKG2D), NKG2A/CD94, NKp46, and others (46, 47) 
(Figures  1 and 2). NK  cells recognize both foreign and self-
antigens expressed by NK-susceptible targets. NK  cells attack 
cells lacking MHC class I molecules specific to the inhibitory 
receptors KIRs on the NK cells (47).
The biological and clinical effects of NK  cells in allogeneic 
transplant have recently been reviewed by Benjamin et al. (50).
The first study utilizing NK cell alloreactivity was shown in 2002 
by the group of Velardi (48). HLA haploidentical— mismatched 
family donors were used to transplant 57 AML patients and 
35 ALL patients. Donor versus recipient NK cell reactivity was 
analyzed in groups with and without KIR ligand incompatibility 
in the graft-versus-host (GvH) direction. Protection from GvHD 
and AML relapse was observed and showed that KIR ligand 
incompatibility in the GvH direction predicted survival in AML 
patients. In contrast, in the ALL patients, KIR ligand incompat-
ibility in the GvH direction had no effect on ALL survival rates. 
In this study, the transplant regimen was myeloablative and 
involved T  cell-depleted grafts and very large doses of CD34 
positive cells/kg, contributing to lack of GvHD and successful 
engraftment.
In a later study using non-myeloablative conditioning (2 Gy 
of TBI with or without fludarabine) and HLA-matched grafts, the 
risk of relapse was less in patients with ligands for all donor KIR, 
but this did not reach significance (51).
PROPHYLACTiC AND PReeMPTive DLi
Animal experiments were designed to demonstrate repletion 
of T cells by DLI after T-cell-depleted transplantation. In dogs, 
donor lymphocytes eliminated residual host hematopoiesis and 
converted mixed chimerism into complete chimerism (52). 
Following these results, prophylactic DLI became part of the 
FLAMSA regimen (fludarabine, cytarabine, amsocrine) for high 
risk AML (53). This regimen was designed for sequential therapy 
of high risk AML with FLAMSA followed by reduced intensity 
conditioning consisting of reduced TBI (4  Gy) or busulphan, 
antithymocyte globulin, and CY. DLI after immunosuppressive 
therapy was stopped for 30 days without development of GvHD. 
A matched pair analysis of patients receiving or not receiving DLI 
showed a significant advantage of patients given DLI; matching 
criteria were CR1 at day 120 from transplantation, absence 
of GvHD, and infection (54). Prophylactic DLI produced 80% 
long-term survival in several studies (55–58), involving around 
340 AML and ALL patients. GvHD was seen in 28% of patients 
given DLI, but it was fatal only in 9% of all patients treated (58). 
However, in a small study of 12 patients in 2001, given DLI pro-
phylactically as early as days 30, 60, and 90 days posttransplant, 
three patients developed GvHD (59). In a study of 15 patients 
treated with alemtuzumab in the conditioning treatment, seven 
patients developed GvHD and, in three patients, it was fatal (60). 
In lymphoma patients, conditioned with a regimen containing 
alemtuzumab for in vivo T-cell depletion followed by DLI for mixed 
chimerism, non-fatal GvHD occurred in 4 out of 17 patients (61). 
In our own unpublished evaluation, using landmark analysis on 
day 180, remissions were sustained in patients transplanted in 
CR. Relapse-free survival was improved in patients transplanted 
in an active phase of the disease. The median time of DLI post-
transplantation was 160  days. Patients with active GvHD or 
relapse prior to 180 days were excluded from the evaluation. Fatal 
GvHD was observed in a patient treated for increasing mixed 
chimerism following an infection with Noro virus and another 
patient with upper respiratory tract infection. Viral infections can 
induce HLA class II antigens on non-hematopoietic cells leading 
to GvHD (62). Prophylactic antibiotic and virostatic treatment 
has been used to improve outcome.
Besides DLI for mixed chimerism, preemptive DLI can be 
given to patients with minimal residual disease (MRD) after 
FiGURe 2 | Natural killer (NK) cell inhibitory and activatory receptors and their ligands. Major inhibitory and activating receptors on NK cells and their 
cognate ligands on target cells. Image adapted from Ref. (46).
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transplantation. In CML, cytogenetic or molecular relapses 
indicate presence of residual disease without clinical signs; DLI 
have been effective in these patients with responses of >80% 
(16, 19, 47). In AML, there are a few molecular markers with 
sufficient sensitivity for diagnosing MRD. Monitoring WT1 gene 
transcripts has been found to predict relapse and the response 
to DLI (63) and RUNX1-RUNX1T1 transcript levels in patients 
with t(8;21) AML (64) pre DLI has been found to be predictive 
of a higher relapse incidence. MRD in acute leukemia in children 
and adults has been well documented (65) using a combination of 
flow cytometry and polymerase chain reaction, the latter for the 
detection of leukemia-specific fusion transcripts or clone-specific 
immunoglobulin including T  cell receptor genes. In relapsed 
acute leukemia, a combination of gene transcript levels and four 
color flow cytometry, MRD monitoring has been found to predict 
a second relapse post-DLI (66). In myeloma, several groups have 
studied prophylactic or preemptive DLI (67–69), the rate of 
durable remissions is low, but secondary treatment is efficacious 
and survival is excellent.
The successful use of CML in DLI in the 1990s has been 
substantially reduced due to the reduced number of allo-HSCT 
for CML, to approximately 1% (70), by the success of tyrosine 
kinase inhibitors (TKIs) to treat CML. The family of TKI’s is 
capable of restoring complete molecular remission after relapse 
(71–73). CML relapse, molecular cytogenetic, or hematological 
has been reported as ranging from 16, 30, and 54%, respectively, 
using data from the Chronic Malignancies Working Party for the 
EBMT and based on 500 HSCT transplants from 1968 to 2004. 
The use of DLI in these cases was most successful if pre DLI fac-
tors such as chronic GvHD, cell dose, patient and donor gender 
mismatch, as previously described was taken into account (31).
In contrast, relapse after allo-HSCT for the other types of 
leukemia is further dependent in AML, on the age of the patients, 
disease status pre allo-HSCT, the AML sub types (primary or 
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secondary), cytogenetic and molecular markers, type of condi-
tioning and stem cell source (74–79). AML patients relapsing 
after allo-HSCT rarely responded to DLI although remissions 
have occurred in selected cases (26).
Use of DLI in a large cohort of 399 AML patients, collated from 
the Acute Leukemia Working Party of the EBMT, was associated 
with 21% overall patient survival at 2 years, compared with 9% 
for patients not receiving DLI (33). Better outcome was associ-
ated with lower tumor burden at relapse, female gender, favorable 
cytogenetics, and with patients in hematological remission before 
DLI or at the time of DLI. From these studies, an algorithm for 
the clinical use of DLI was developed for use in the treatment 
of relapsed AML, which included the sequence of cyto reductive 
chemotherapy or indication of CR1 prior to DLI (80).
Relapse after ALL varies from 30 to 35% depending on whether 
the patients have undergone a HLA-matched sibling transplant or 
matched unrelated donor (MUD) transplant (81), and response 
to DLI has been recorded at 50% with survival rates improved in 
patients who developed acute GvHD after DLI (82).
COMPLiCATiONS OF DLi
Graft-versus-Host Disease
Early experiments in canine, rat, and mice transplant models 
demonstrated no GvHD following infusion of non-sensitized 
donor lymphocytes into stable chimerisms (18–21).
This observation led to the concept that DLIs may be used to 
improve engraftment and accelerate immune reactivity without 
the occurrence of GvHD in a stable human chimera.
Contrary to the results in animal experiments with dogs and 
mice, GvHD was seen in humans given DLI (83). There are a great 
number of differences that may account for this. Unlike human 
patients, animals used for experiments are of younger age and are 
kept in protected environments, minimizing chronic infections 
and immune cross reactivity. More importantly, differences exist 
in the underlying malignant disease and its impact on alloim-
munity as well as prior chemotherapy, depleting lymphocytes and 
ablating regulatory T cells (84).
Attempts at preventing GvHD included depleting cytotoxic 
CD8-positive T  cells from the transfusion (85), arming T  cells 
with suicide genes (86), and the administration of escalating 
doses (87), which was widely adopted for the treatment of recur-
rent CML (88).
An important role in the generation of GvHD after DLI is 
played by viral infections and/or reactivations of viruses (62, 89). 
Antiviral and antimicrobial prophylaxis has, therefore, prevented 
viral infections and improved the response to DLI.
In addition, studies by the Chronic Malignancies Working 
Party of the EBMT (29, 83, 90) have shown that up to 40% of 
patients with secondary GvHD post-DLI had a twofold to three-
fold increased risk of death, compared to patients without GvHD. 
The best results following DLI are obtained when patients obtain 
remission without GvHD, thus separating GvL from GvHD in 
these patients (90–92).
A recent study by Radujkovic et al. aimed to identify pre-DLI 
factors, which may predict survival in remission without secondary 
GvHD in patients with relapsing CML. The study identified that 
the presence of chronic GvHD before DLI and less than 1 year 
between the allo-HSCT and DLI were associated with inferior 
survival. The likelihood of survival in remission without GvHD 
was most prevalent, i.e., 50% at 5 years follow-up, when DLI was 
given without prior chronic GvHD and greater than 1-year post 
allo-HSCT for molecular and/or cytogenetic CML relapse.
For hematological relapse, a T  cell dose of greater than 
50  ×  106/kg, the donor–recipient gender mismatch and prior 
chronic GvHD were the worst prognostic factors.
Initial studies showed that starting the transfusion of donor 
cells at low cell numbers followed by escalating doses until 
response or induction of GvHD reduces the incidence and sever-
ity of GvHD but preserves a GvL effect (87, 93).
Guglielmi et  al. subsequently analyzed 344 CML patients 
treated by DLI and their study found that the initial cell dose 
was given based on donor type (HLA-identical sibling or HLA 
matched volunteer unrelated donor), T  cell depletion, GvHD 
prior to relapse, relapse type (cytogenetic, molecular, and 
hematological), and year (90). The lower the initial cell dose, the 
high number of subsequent transfusions were given to achieve a 
response and the incidence and severity of GvHD and myelosup-
pression increased with the higher initial cell dose of greater than 
0.2 × 106 MNC/kg. Factors such as donor type, gender of donor, 
disease phase at transplantation, T cell depletion, interval from 
transplantation to DLI, GvHD prior to relapse and relapse type, 
all influence outcome post-DLI and potential incidence of GvHD 
and prolonged survival.
Myelosuppression
Pancytopenia and marrow aplasia have been observed in 
patients treated with DLI for hematological relapse of CML (92) 
and transfusion of marrow from the original donors restored 
hematopoiesis (94). Sometimes, myelosuppression and marrow 
aplasia were sudden and related to acute GvHD (95). This type of 
phenomenon can be explained by the incoming donor marrow 
removing leukemic hematopoiesis prior to donor hematopoiesis 
being fully established. Lack of recovery in some patients may 
also be explained by too few stem cells in the donor graft to 
sustain hematopoiesis.
iMPROveMeNT OF THe ReSPONSe
Complete cytogenetic responses were achieved initially in 
patients with CML who had been treated with massive doses 
of donor lymphocytes (>108/kg) and interferon-α (IFN-α) but 
had failed to respond to IFN-α alone. Responses were better 
in patients treated with myeloablative conditioning and T cell-
depleted grafts than in patients with non-myeloablative condi-
tioning and peripheral blood (PB) stem cells containing high 
proportions of T cells (29, 96). The better response of myeloid 
forms of leukemia led to the hypothesis that direct antigen 
presentation by leukemia-derived DC may play a major role in 
the activation of donor T  cells (91). IFN-α improves the GvL 
effect of low doses of DLI and the combination of IFN-α and 
granulocyte macrophage-colony stimulating factor (GM-CSF) 
improved antigen presentation and generation of cytotoxic 
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T cells in CML (97). Consequently, patients not responding to 
IFN-α and DLI responded to the combination of DLI, IFN-α, and 
GM-CSF. Moreover, T cells of CML patients displayed reduced 
zeta-chain expression and tended to go into apoptosis, which 
could be reversed by IFN-α (98). Lymphodepletion prior to DLI 
may enhance the anti tumor effect of the infused T cells, however, 
this can cause more GvHD (84).
Future potential improvements may come from the treat-
ment with checkpoint inhibitors in order to increase T  cell 
activation by inhibiting downregulation (99). Preliminary 
reports have shown feasibility of single doses of ipilimumab 
with blockade of CTLA4, without producing GvHD (100). An 
attractive way of treatment may be the use of central memory 
T  cells that maintain a memory immune reaction without 
producing GvHD (101).
Antigen-Specific T Cells
In acute leukemia, the pace of the disease is too fast to allow 
the development of immune reactions against the leukemia as 
observed for CML. Therefore, the generation of specific tumor 
immune T cells for the rapid elimination of leukemia cells have 
been investigated, and there are several candidate antigens, which 
have been used in assessing immune reactions to leukemia and 
induction of remission.
Leukemia-Associated Antigens (LAAs)
Leukemia-associated antigens are often overexpressed in 
leukemia blasts and absent in normal tissue such as Wilms 
tumor 1 (WT-1), preferentially expressed antigen in melanoma 
(PRAME), melanoma family antigen (MAGE), receptor for 
hyaluron mediated motility (RHAMM), testis antigens like New 
York esophageal squamous cell carcinoma-1 cancer-testis antigen 
(NY3ESO), and granulocyte antigens such as PR1 (a 9 amino acid 
HLA-A*0201-restricted peptide derived from proteinase3).
The most widely studied antigen is coded by WT-1, a gene 
involved in Wilms tumor and present in about 77% of AML (102). 
Cytotoxic T cells against WT-1 kill AML stem cells preventing 
engraftment in NOD/SCID mice (103). Most immune reactivities 
found after DLI against any of these antigens are weak. Moreover, 
immune reactivity against autologous antigens is frequently sup-
pressed by mechanisms of tolerance mediated by, e.g., regulatory 
T-cells (Tregs) or inhibitory cytokines (104). Peptides presented 
by foreign HLA antigens can be immunogenic by different con-
figurations (105). It has been shown in a mouse model that T cell 
receptors cloned from HLA-different T cells can be transduced 
into autologous T cells to maintain immunity (106). Mispairing 
of T cell receptor chains with endogenous TCR chains could be 
avoided by lentiviral (LV) transfer and more recently by silenc-
ing endogenous TCR with endonucleases prior to transduction 
(107). Our own results correlated stable remission after HSCT 
with the presence of higher proportions of LAA-specific T-cells. 
The simultaneous detection of two different LAA-specific (CD8-
positive T-cells) correlated with a higher chance of long-lasting 
remission. Moreover, we detected clonally restricted (PRAME-)
specific T-cells and, in general, an enrichment of (effector)
memory T-cells in cases with stable remission (102).
Our studies focused on patients after HSCT and might, 
therefore, be in accordance with the finding of PRAME reactive 
cytotoxic T precursor cells in healthy donors and not in AML 
patients (108). Encouraging results for PRAME as a target for 
immunotherapy in leukemia were, however, reported by Rezvani 
and colleagues (109). Immune response to RHAMM has also 
been elicited by vaccination (110). At present, lasting success 
using anti-LAA T cells have not been reported.
Leukemia-Specific Antigens
Leukemia-specific antigens are antigens coded for by a muta-
tional event in the leukemic clone. A unique translocation is the 
cause of CML, and the peptides derived from this gene fusion are 
presented by HLA antigens, the most immunogenic by HLA A3. 
In addition, DC in CML patients have the BCR/ABL transloca-
tion and can stimulate allogeneic T  cells, inducing a cytotoxic 
T cell effect (97).
Single cases of enduring responses and immunity to the 
fusion peptide have been reported with peptide vaccine and 
interferon-α (104). In AML, many different mutations make the 
production of a vaccine to leukemia-specific antigens difficult, 
but cytotoxic T cells against nucleophosmin (NPM1) have been 
reported (111). NPM1 may be a preferable target, because of its 
presence on leukemia stem cells. New possibilities may arise from 
the detection of immune inhibitors of T cell activity, which may 
be reconstituted by check point inhibitors enabling T cells to react 
to whatever antigen is recognized. In AML and myeloid malig-
nancies, other mechanisms (33) of T cell suppression may also be 
important. For example, blockade of CD47 expression on tumor 
cells, driving macrophage T cell and dendritic cell activation leads 
to tumor cell killing (33).
Minor Histocompatibility Antigens (mHAs)
Minor histocompatibility antigens are responsible for graft rejec-
tion and GvHD in HLA-identical sibling transplants, they may be 
effective in GvL, if these antigens are expressed on hematopoietic 
cells. The reaction against hematopoietic cells of the patient is 
irrelevant, because hematopoiesis is substituted by donor cells. 
Both CD4-positive and CD8-positive T cells respond to leukemic 
or minor histocompatibility antigens. In the latter case, cytotoxic 
T cells have been generated against CML, which have induced 
remission and shown to be correlated with the presence of cyto-
toxic T  lymphocytes against minor histocompatibility antigens 
HA1 and HA2 (112). In an EBMT study, responses of patients 
with recurrent CML were only seen in those with an allogeneic 
donor, syngeneic twin donors did not respond (29). There are 
mHAs with a tissue distribution restricted to the hematopoietic 
system (113) and mHA expressed in all tissues. The strongest 
mHAs are those coded by the Y chromosome (114). Y chromo-
some antigens-directed T cell responses show strong antileuke-
mic effects (115), but they may also produce GvHD. mHA also 
produce peptides presented by both HLA class I and HLA class II, 
as well as eliciting antibodies against themselves (116). We have 
investigated Y chromosome genes by comparing leukemic blasts 
with normal monocytes, and we found four genes overexpressed 
in AML (102). Peptides of the gene products were loaded onto 
FiGURe 3 | Mechanisms of the graft-versus-leukemia (GvL) effect. 
Host dendritic cells (DCs), activated by CD4-positive T cells, mature and can 
then activate CD8-positive T cells via a “license to kill” and attack leukemia 
cells. The leukemia cells themselves can also differentiate into self DC.
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T2 cells and cytotoxic T cells could be produced against two of 
the four antigens. As demonstrated in a canine model, we could 
demonstrate that female dog-effector-T-cells could be specifically 
stimulated against male chromosomal (UTY−) gene products 
(116).
The search for new mHA was expanded to study the reactivity 
of T cells against antigens and overlapping peptides of genotyped 
lymphoblastoid cell lines (HapMap-Project) (117). Several new 
antigens were found, but the majority of reactions did not show 
significance probably due to additional factors provided by the 
microenvironment (118).
Production of DC of Leukemia  
Origin (DCleu)
Effective antigen presentation is essential in GvL reactions. 
GM-CSF has been effective in the production of DC of leukemia 
origin (DCleu), which were able to induce cytotoxic T cells (119). 
Inhibition of cytotoxicity was greater with antibody against HLA 
class I than antibody against HLA class II. Production of DC from 
AML leukemia blasts was extensively studied by Schmetzer and 
colleagues (102, 120) (Figure  3). It could be shown that DCleu 
could be successfully generated from blood samples in every 
AML patient using methods of DC generation containing dif-
ferent mixtures of immune-modulatory factors, GM-CSF, IL-4, 
TNF-α, FLT3-L, IL-1β, IL-6, PGE2, bacterial lysate of streptococ-
cus pyogenes (PICIBANIL), or calcium ionophore.
Moreover, Schmetzer’s group correlated a successful ex vivo 
generation of DCleu from AML blasts before HSCT with a clinical 
response to HSCT or DLI (102), which may suggest a central role 
of DCleu in priming antileukemic T cells.
In vivo Schmetzer’s group has shown that rats heavily diseased 
with promyelocyte-like leukemia and treated with DCleu-inducing 
Kits GM-CSF with Picibanil, prostaglandin 1 or 2 (PGE1 or 
PGE2) (patent-number 10 2014 014 993) showed a highly 
significant reduction of blasts, an increase of memory like T-cells, 
and a decrease of Treg after two Kit-applications in only 9 days, 
therefore, suggesting that as proof of principle, a DCleu induction 
in vivo could lead to T-cell activation resulting in a specific blast 
reduction. Our ongoing research focuses on the transfer of this 
strategy to patients with AML (121) [Christoph Schmid and 
Helga Schmetzer, personal communication; (102, 122)].
Some patients with AML relapsing after transplantation could 
be induced into remission by treatment with low-dose cytarabine, 
mobilized donor cells including PB stem cells and post-grafting 
GM-CSF (123). GvHD occurred on the day after T  cells were 
administered. The remission rate was doubled compared to the 
results of an EBMT study and some patients survived in long-
term remission without further treatment. Risk (33) factors for 
failing treatment were early relapse (less than 180 days) and fail-
ure to respond to low-dose cytarabine. In the EBMT study, similar 
risk factors were defined and long-term survival was only seen 
in patients treated with DLI or second transplants after achiev-
ing CR1 (80). Several centers have shown efficacy of repeated 
treatments with azacitidine and DLI also establishing long-term 
remission in some patients (124). Azacitidine and cytarabine have 
the potential to induce differentiation of blasts, new targeted drugs 
like sorafenib (125) and midostaurin (126) may also be helpful 
in Fms-related tyrosine kinase 3 (FLT-3)-positive leukemia or 
panobinostat, an oral deacetylase inhibitor for MM (127, 128).
Both cytokines and targeted drugs enable leukemia blasts 
to differentiate into DC which, by presenting antigen, provide 
stimulating signals to donor naïve T  cells (129). Both reactive 
CD8-positive and CD4-positive T  cells have been found in 
patients responding to DLI (130). In vitro generated T cell cytotox-
icity predominantly consisted of CD8-positive T cells, but CD4-
positive cytotoxic T cells were also present (119). Schmetzer et al. 
have shown that T-cell clonality was more restricted after ex vivo 
DCleu induction compared to blast stimulation, pointing to a role 
of DCleu to efficiently enrich selected T-cell-clones. Interestingly, 
T  cells with the same Vβ chain of the T  cell receptor that was 
observed in vivo were also found in in vitro cultures (131).
The production of CD4-positive T cells against HLA-class II 
restricted minor antigens have the advantage that HLA-class II 
antigens are only expressed on cells of the hematopoietic system. 
The GvH reaction of allogeneic T  cells, therefore, spares non-
hematopoietic organs and is operationally leukemia specific (132). 
However, there are limitations to this approach, since inflam-
mation of healthy tissue increases the expression of HLA-class 
II on non-hematopoietic cells and induces GvHD. Like normal 
hematopoietic stem cells, leukemia stem cells are quiescent and 
do not express HLA-class II antigens (133). Therefore, HLA-class 
I restricted CD8-positive T  cells may be further required for 
complete elimination of leukemia stem cells.
The hypothetical mechanism behind the GvL effect is that 
DCs become activated by donor CD4-positive T cells and, once 
mature, the DCs activate CD8 positive T cells by a mechanism 
called “license to kill” (134). These also react against leukemia 
stem cells until the pool of these cells is depleted. CD8 positive 
naïve T  cells, therefore, become involved in the GvL reaction 
with antigens involving HLA class II and class I peptides being 
the optimal target (Figure 3). Presumably, repeat interactions of 
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host/leukemia-derived DCs and donor CD4-positive T cells are 
necessary for sustained GvL effects. Direct antigen presentation 
by host/leukemia DCs may also be a further mechanism.
Another possible way the GvL reaction is maintained is by 
central memory T cells that do not require CD4 help for sustained 
GvL effects. Precursor cells recognizing LAA and mHA are found 
in low frequencies in the bone marrow of healthy donors, and 
these can be expanded by encountering some of these antigens 
in the patient. Examples of the efficacy of memory T  cells are 
virus-specific T cells that can be selected from immune stem cell 
donors and transferred to the patient (135). As these cells can 
expand in vivo, the presence of central memory T cells recogniz-
ing antigens on leukemia cells in the graft is the most important 
criteria for successful GvL effects. Ex vivo data of Schmetzer and 
colleagues showing increased memory T  cell proportions after 
T cell stimulation with DCleu, compared to blasts, and reduced 
naïve T cells support this view (102).
MeCHANiSMS OF A GvL  
eFFeCT—NK CeLLS
T cells and NK cells in the donor graft eliminate residual leukemia 
cells in the patient by T cell interaction with leukemia-specific 
antigens or mHA, activated NK  cells interact with allogeneic 
targets lacking killer immune receptors (48, 136) (Figure 2).
Natural killer cells are the major players of innate immunity 
with the fastest reconstitution in vivo. NK cells are the earliest 
lymphocytes recovering after HSCT and due to delayed recon-
stitution of a functional T  cells repertoire, NK  cells are a vital 
lymphocyte subset exerting antileukemic effects and have been 
linked to reduction in relapse rates or improved disease-free 
survival (137). Nevertheless, as recently reviewed by Zhao et al., 
the reconstitution of NK  cells is influenced by many factors, 
including the conditioning regimen, level of T cell depletion, and 
the use of immune suppression after transplantation (138).
KiR–Ligand interactions and  
HSCT Outcome
Many clinical studies have linked NK cells to successful outcomes 
following HSCT. For instance, the donor KIR genotype plays an 
important role in the development of infections posttransplant. 
Recipients of unrelated donor HSCT from donors with an 
activating (KIR) (B/x) genotype have less infectious (bacterial) 
complications than those with an A/A KIR genotype, because 
of the enhanced NK cell function (139). It also has an effect on 
survival post HSCT; in a small study of HLA-matched T  cell-
replete sibling transplants, better overall survival was associated 
with the presence of group B KIR haplotypes in the recipient 
and the absence in the donor (140). Conversely, three donor B 
haplotype KIR genes have been reported to be associated with 
reduced relapse and improved overall survival in a study of 
HLA-matched T cell-replete sibling transplants (141), and in a 
cohort transplanted for AML, donor possession of group B KIR 
haplotypes was associated with improved relapse-free survival 
but a higher incidence of chronic GvHD (142). The group B KIR 
haplotype KIR3DS1 in the donor has been found to be associated 
with decreased acute GvHD in MUD transplantation; however, 
this effect appears to be unique to this specific B allele (142).
Moreover, in haploidentical HSCT, NK  cells may express 
inhibitory killer immunoglobulin-like receptors that are not 
engaged by any of the HLA class I alleles present on recipient cells. 
Such “alloreactive” NK cells greatly contribute both to eradication 
of leukemia blasts escaping the preparative regimen and to clear-
ance of residual host DCs and T lymphocytes (thus preventing 
GvHD and graft rejection, respectively) (143).
Furthermore, in umbilical cord blood (UCB) transplants for 
acute leukemia in first CR1, patients with KIR ligand incompat-
ible donors had improved overall survival (57 versus 40%) and 
decreased relapse (20 versus 37%) when compared with those 
without these incompatibilities. Benefits of KIR ligand incom-
patibility were most striking among patients with AML although 
UCB recipients with ALL also had a trend toward improved 
leukemia-free survival (144).
IPH2101 is a human IgG4 monoclonal antibody directed 
against inhibitory KIRs (KIR2DL-1, -2, and -3), which blocks 
KIR–ligand interaction and augments NK  cell-mediated lysis 
of HLA-C-expressing tumor cells. A phase I trial of IPH2101 
(NCT00552396) was conducted in 32 patients with relapsed/
refractory MM suggesting that IPH2101 is safe and tolerable at 
doses that achieve full inhibitory KIR saturation (145).
In Vitro and In Vivo induction  
of a GvL effect
Lentiviral vectors have been successfully used to transduce both 
T and NK-cell lines. Chimeric antigen receptors (CARs) are 
synthetic engineered receptors that target surface molecules in 
their native conformation, independent of MHC and of antigen 
processing by the target cells (146). For example, CS1 is a surface 
protein highly expressed on MM cells and is amenable to tar-
geting with CS1-specific CARs. CS1-CAR-transduced NK cells 
showed stronger cytotoxic activity against CS1-expressing MM 
cells and showed increased IFN-γ production compared with 
mock-transduced NK  cells. In an orthotopic MM xenograft 
model, adoptively transferred CS1-CAR-NK-92 cells suppressed 
the growth of human IM9 myeloma cells and significantly pro-
longed mouse survival (147). Moreover, CAR-NK cells may be 
safer compared with that of CAR-T cells, because of lack of in vivo 
clonal expansion and cytokine storm.
Novel research techniques use either all or part of an antibody 
structure to deliver enhanced effector activity to the tumor 
site. Bi-specific killer engagers (BiKEs) are constructed with a 
single-chain Fv against CD16 and a single-chain Fv against a 
tumor-associated antigen. The mechanisms by which BiKEs 
potentiate NK effector functions include intracellular calcium 
mobilization through direct CD16 signaling (148). Fully human-
ized CD16 × CD33 BiKEs have been shown to trigger NK-cell 
activation in  vitro against CD33+ AML cell lines and primary 
refractory CD33+ AML targets (149). BiKEs enhance degranula-
tion and cytokine production by NK cells derived from patients 
with MDS and cultured with CD33+ AML cell lines, irrespective 
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of disease stage and age stratum (150). A potential drawback 
of this approach is the relatively short half-life of the antibody 
constructs, with limited trafficking to the tumor site.
Ex Vivo expansion of NK Cells and 
induction of GvL effects
There is no indication to suggest that human GvHD is linked 
with NK cell infusions, thus increasing the NK cell dose is one 
useful approach to improve the antileukemia activity. However, 
for clinical therapy one significant limitation is that the numbers 
of NK cells/kg recipient weight obtained by leukophoresisis are 
relatively small (~2 × 107/kg).
Classically, GMP-compliant NK-cell products have been 
generated from peripheral blood mononuclear cells collected by 
apheresis (151). IL-15 was used to promote NK-cell proliferation 
and survival and has been variably used in GMP-grade laboratory 
protocols. Different expansion methods rely on human feeder 
cells including artificial antigen-presenting cells that are modi-
fied with costimulatory molecules, such as CD137 ligand and 
 membrane-bound (mb) IL-15 or IL-21. However, expanded 
NK cells may affect the replicative potential and long-term viabil-
ity of in vivo infusion. For instance, in NK cells, both FAS expres-
sion and susceptibility to apoptosis are increased after co-culture 
with IL-2 or with feeder cells (152). In addition, some receptors 
required for homing were reduced in expanded NK cells, such 
as CCR7, a member of the G protein-coupled receptor family. 
In line with this, NK  cells expanded with genetically modified 
K562 cells were shown to predominantly express a CD16+CD56+ 
phenotype, with no detectable CCR7 (153, 154). To obviate this, 
NK cells have been co-cultured with genetically modified, IL-21/
CCR7-expressing K562 cells, in order to transfer CCR7 onto 
NK cells via trogocytosis. CCR7 expression occurred in 80% of 
expanded NK cells within 1 h (154).
Umbilical cord blood is an emerging source of NK cells for 
clinical applications and also provides an in vitro system to ana-
lyze NK development (155). However, NK cells from PB and UCB 
differentially express cytokine receptors, for instance, IL-15Rα 
being preferentially detected on UCB NK  cells and IL-12Rβ1 
and IL-18α receptors being primarily found on PB NK  cells 
(156, 157). This implies that, unlike PB NK  cells that are fully 
activated by IL-2 alone, UCB NK  cells may require additional 
cytokine stimuli (158). For instance, the addition of tacrolimus 
and low-molecular-weight heparin significantly enhances NK-cell 
expansion induced by IL-2, IL-15, and anti-CD3 mAbs (159).
Like UCB, human embryonic stem cells (ESCs) as well as 
induced pluripotent stem cells (iPSCs) are also potential sources 
of phenotypically mature and functional NK  cells. ESCs and 
iPSCs were first used to produce hematopoietic progenitors with 
the “spin embryonic body (EB)” method, in which defined num-
bers of cells were spin-aggregated in serum-free medium. Spin 
EB-derived cells were then tested in a feeder-free and serum-free 
system containing NK-cell promoting cytokines, i.e., IL-3, IL-7, 
IL-15, SCF, and Flt3-L. Importantly, NK cells developed in similar 
numbers, phenotype, and functional characteristics as those dif-
ferentiated with the use of murine stromal cells (160).
Several malignant NK  cell lines were established and used 
for clinical trials in some countries, as reviewed elsewhere 
(161). The adoptive transfer of NK  cell lines has theoretical 
advantages related to lack of expression of inhibitory KIRs, lack 
of immunogenicity, and ease of expansion. For instance, K562-
mb15-41BBL cells were used to expand NK  cells transduced 
with an anti-CD19-BB-ζ CAR and showed enhanced reactivity 
to CD19+ leukemia cells (162). Similar to K562-mb15-41BBL, 
K562 genetically modified to express mbIL-21, or to co-express 
the ligand for 41BB and the NKG2D ligand MICA (K562-4-
1BBL-mMICA), have been shown to promote large-scale expan-
sion of NK  cells with enhanced antitumor in  vitro reactivity 
(163–165). Moreover, EBV-immortalized B-lymphoblastoid cells 
(EBV-BLCL) are known to strongly support NK  cells in  vitro 
expansion and antitumor activity (166–168). Escudier and col-
leagues used 35-Gy-irradiated LAZ 388 EBV-BLCL for the ex 
vivo expansion of NK cells from patients with metastatic renal cell 
adenocarcinoma. Based on their protocol, a phase I clinical trial 
is currently investigating technical feasibility and clinical efficacy 
of large-scale NK infusions (up to 1 × 109/kg) in cancer patients 
receiving bortezomib administered with the scope of increasing 
susceptibility of tumor cells to NK-mediated lysis (169, 170).
In addition, Schmetzer and colleagues have shown recently 
that invariant (i)natural killer T ((i)NKT) and cytokine-induced 
killer (CIK) cells, where both cell types combine the characteristics 
of T as well as NK cells, and their subsets are promising cells in 
the induction of antileukemic reactions. Preliminary findings 
show that proportions and compositions of these cells provide 
prognostically relevant data for patients with AML, ALL, and CLL. 
Moreover Kit-treated AML-blasts (resulting in DCleu) induce a shift 
not only of T-cells but also of iNKT, NK, and CIK cells counts and 
proportions, correlating in improved antileukemic activity against 
AML blasts and implying cross talk between these cells (171).
TReG THeRAPY AND iTS eFFeCTS  
iN GvL AND ReLAPSe
The effects of Treg therapy for GvHD, GvL, and relapse post-
HSCT has been recently summarized by Romano et  al. (172). 
There have been several trials investigating the safety and efficacy 
of Treg-based therapy, the first recorded trial was reported in 
2009 where in vitro expanded CD4+ CD25+ CD27− cells were 
used for the treatment of two patients with either acute GvHD or 
chronic GvHD (173). The patient with chronic GvHD showed a 
significant improvement of symptoms and the patient with acute 
GvHD had a transient improvement, however, due to the very 
low patient number no conclusions on the effect of Treg therapy 
on relapse were drawn. Another trial in 2011 reported the use 
of expanded Tregs from third party UCB in 23 patients with 
acute GvHD (174), no toxicities were documented and GvHD 
was reduced with no effect on relapse when compared with 108 
historical controls.
Edinger and Hoffmann reported a small phase I safety trial 
(175) where nine patients at high risk of relapse post-HSCT were 
treated with freshly isolated donor Tregs, then 8  weeks later, 
conventional T  cells were given to promote GvL activity and, 
as in the previous trial, there was no increased risk of relapse. 
In 2014, a group reported a trial in 43 patients with high risk 
leukemia, using freshly isolated donor Tregs pre-haploidentical 
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HSCT, to avoid intensive ex vivo depletion of T cells in the graft. 
This protocol showed for the first time that adoptive immuno-
therapy with Tregs protected against GvHD compared to patients 
undergoing conventional haploidentical transplants. In addition, 
the incidence of relapse was reduced, suggesting that Tregs do 
not target GvL (176). More recently, a trial of the infusion of 
expanded Tregs and IL-2 for chronic GvHD has been reported. 
The study showed that the stability and functionality of the 
Tregs in vivo was maintained due to the increase in the number 
of T cells post-infusion. There was no toxicity nor exacerbation 
of chronic GvHD or other adverse immune reactions, chronic 
GvHD responded but the trial had only five patients and two of 
these patients developed non-hematological malignancies sug-
gesting that Tregs may contribute to a tumor escape mechanism 
via suppression of the immune response (177).
CONCLUSiON
Many questions remain to be addressed in order to optimize the 
GvL effect of DLI for treating and preventing relapse and Table 1 
summarizes the main features of this review. In CML, long-term 
remissions can readily be obtained by the treatment with low-
dose IFN-a and DLI, in AML, long-term remissions may be 
obtained by a more aggressive approach involving mobilized 
stem cells and GM-CSF following cytarabine or repeated treat-
ments with targeted drugs like azacytidine, sorfenib, midos-
taurin, immune-modulatory/blastmodulatory Kits, and DLI. 
Better results may be achieved with prophylactic or preemptive 
DLI and/or treatment with blast-modulating Kits combining 
myeloid cell-differentiating factor GM-CSF with “danger”-
signaling and DC-maturation-inducing factors (e.g., PGE1, 
PGE2, or Picibanil) addressing myeloid blasts and converting 
them to DCleu—resulting in an in vivo stimulation of antileuke-
mic T-cells. In addition to measuring minimal residual disease 
(MRD) or mixed chimerism, prophylaxis for viral infections 
may be required to avoid triggering of GvHD.
In myeloma, antigen presentation may be a problem and 
dendritic cell vaccines as well as low-dose lenalidomide may be 
helpful for sustained remissions. Antibodies-engaging effector 
cells are still to be studied in the allogeneic situation. Finally, 
TAbLe 1 | Overview of the chapter and summary of main points.
Chapters Sub headings Reference Main points
Introduction (1–16) Introducing hematopoietic stem cell transplantation (HSCT), graft-versus-leukemia 
(GvL), and residual disease
Clinical results using 
DLI for relapse after 
hematopoietic cell 
transplantation
(17–34) First studies of donor lymphocyte infusion (DLI) for chronic myeloid leukemia 
(CML) and results for acute myeloid leukemia (AML) and acute lymphoid  
leukemia (ALL)
The history of the role of 
T cells and NK cells in the 
GvL effect
(35–48, 50, 51) Early studies of the role of T cells and natural killer (NK) cells
Prophylactic and 
preemptive DLI
(52–81) Studies in CML; AML and ALL
Complications of DLI Graft-versus-host disease (82–92) Factors affecting GvHD occurrence and DLI
Myelosuppression (91, 93, 94) Myelosuppression can be related to aGvHD
Improvement of the 
response
Antigen-specific T cells (29, 90, 95–102) Overview
Leukemia-associated antigens 
(LAAs)
(101–109) Overview of antigens expressed in leukemia blasts and absent on normal tissue
Leukemia-specific antigens (33, 96, 103, 110) These are antigens coded for by the mutation event in the leukemic clone
Minor histocompatibility antigens 
(mHAs)
(29, 111–117) mHA, responsible for graft rejection and GvHD in HLA identical siblings
Production of DC of leukemia 
origin (DCleu)
(80, 101, 118–133) Cytokines and certain drugs cause leukemic blasts to differentiate into DC, which 
can then stimulate GvL
Mechanisms of a GvL 
effect—NK cells
(48, 136–138) Activated donor NK cells induce GvL by interaction with allogeneic targets lacking 
killer immune receptors
KIR–ligand interactions and HSCT 
outcome
(139–145) Regulate the killing function of NK cells, most are inhibitory, they are pleomorphic 
and their genotype is important in GvL
In vitro and in vivo induction of a 
GvL effect
(146–150) Chimeric antigen receptors (CARs) T cells and CAR NK cells have shown promise 
and more recently Bi-specific killer engagers have been developed
Ex vivo expansion of NK cells and 
induction of GvL effects
(151–170) NK cells can be expanded from peripheral blood mononuclear cells, umbilical 
cord blood, ECSs, and also malignant NK cells lines but all have their limitations
Treg therapy and its effect 
in GvL and relapse
(172–177) Tregs shown to reduce GvHD and do not induce relapse, but patients may 
potentially develop non-hematological malignancies 
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